Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
- PMID: 34204243
- PMCID: PMC8233978
- DOI: 10.3390/pathogens10060763
Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation
Abstract
Coronavirus disease 2019 (COVID-19) patients sometimes experience long-term symptoms following resolution of acute disease, including fatigue, brain fog, and rashes. Collectively these have become known as long COVID. Our aim was to first determine long COVID prevalence in 185 randomly surveyed COVID-19 patients and, subsequently, to determine if there was an association between occurrence of long COVID symptoms and reactivation of Epstein-Barr virus (EBV) in 68 COVID-19 patients recruited from those surveyed. We found the prevalence of long COVID symptoms to be 30.3% (56/185), which included 4 initially asymptomatic COVID-19 patients who later developed long COVID symptoms. Next, we found that 66.7% (20/30) of long COVID subjects versus 10% (2/20) of control subjects in our primary study group were positive for EBV reactivation based on positive titers for EBV early antigen-diffuse (EA-D) IgG or EBV viral capsid antigen (VCA) IgM. The difference was significant (p < 0.001, Fisher's exact test). A similar ratio was observed in a secondary group of 18 subjects 21-90 days after testing positive for COVID-19, indicating reactivation may occur soon after or concurrently with COVID-19 infection. These findings suggest that many long COVID symptoms may not be a direct result of the SARS-CoV-2 virus but may be the result of COVID-19 inflammation-induced EBV reactivation.
Keywords: COVID-19; EBV; Epstein–Barr virus; Epstein–Barr virus reactivation; PACS; SARS-CoV-2; chronic COVID syndrome; coronavirus; long COVID; post-acute COVID-19 syndrome.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.BMC Infect Dis. 2023 Nov 15;23(1):800. doi: 10.1186/s12879-023-08820-w. BMC Infect Dis. 2023. PMID: 37968601 Free PMC article.
-
Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis.J Clin Virol. 2007 Apr;38(4):292-7. doi: 10.1016/j.jcv.2007.01.006. Epub 2007 Mar 1. J Clin Virol. 2007. PMID: 17336144
-
COVID-19 associated EBV reactivation and effects of ganciclovir treatment.Immun Inflamm Dis. 2022 Apr;10(4):e597. doi: 10.1002/iid3.597. Immun Inflamm Dis. 2022. PMID: 35349757 Free PMC article.
-
Epstein-Barr virus-acquired immunodeficiency in myalgic encephalomyelitis-Is it present in long COVID?J Transl Med. 2023 Sep 17;21(1):633. doi: 10.1186/s12967-023-04515-7. J Transl Med. 2023. PMID: 37718435 Free PMC article. Review.
-
Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.J Clin Pathol. 2019 Oct;72(10):651-658. doi: 10.1136/jclinpath-2019-205822. Epub 2019 Jul 17. J Clin Pathol. 2019. PMID: 31315893 Review.
Cited by
-
Somatosensory abnormalities after infection with SARS-CoV-2 - A prospective case-control study in children and adolescents.Front Pediatr. 2022 Oct 3;10:977827. doi: 10.3389/fped.2022.977827. eCollection 2022. Front Pediatr. 2022. PMID: 36263148 Free PMC article.
-
Epstein-Barr Virus and Human Herpesvirus-6 Reactivation in Acute COVID-19 Patients.Viruses. 2022 Aug 25;14(9):1872. doi: 10.3390/v14091872. Viruses. 2022. PMID: 36146679 Free PMC article.
-
From Viral Infections to Alzheimer's Disease: Unveiling the Mechanistic Links Through Systems Bioinformatics.J Infect Dis. 2024 Sep 10;230(Supplement_2):S128-S140. doi: 10.1093/infdis/jiae242. J Infect Dis. 2024. PMID: 39255398 Free PMC article.
-
Potential Molecular Mechanisms of Rare Anti-Tumor Immune Response by SARS-CoV-2 in Isolated Cases of Lymphomas.Viruses. 2021 Sep 25;13(10):1927. doi: 10.3390/v13101927. Viruses. 2021. PMID: 34696358 Free PMC article.
-
Concurrence between Guillain-Barré syndrome and immune thrombocytopenic purpura possibly induced by long COVID-19.Rev Peru Med Exp Salud Publica. 2022 Jan-Mar;39(1):111-114. doi: 10.17843/rpmesp.2022.391.10687. Epub 2022 Jun 24. Rev Peru Med Exp Salud Publica. 2022. PMID: 35766728 Free PMC article.
References
-
- Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4–e6. doi: 10.1016/j.jinf.2020.08.029. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous
